From Specialty Pharmacy News - The second FDA-approved biosimilar is set to hit the U.S. market by the end of this month. Inflectra (infliximab-dyyb) will launch at a 15% discount to the wholesale acquisition cost of Janssen Biotech, Inc.’s reference drug Remicade (infliximab), according to Pfizer Inc., which will market the biosimilar in the U.S. While that discount may not be as much as industry experts had expected, the drug still should offer some savings. Read more
From Drug Benefit News - As the abuse and misuse of opioids became a national health problem, some state legislators began taking steps to curb this, passing legislation to require insurers to cover FDA-validated abuse-deterrent opioids, as well as put limits on their cost-sharing approaches for members. And while such legislation seems to be having an impact on prescribing, these drugs come at a much higher cost than do opioids without FDA validation, but their… Read more
From Specialty Pharmacy News - A recent conference in Washington, D.C., brought together multiple stakeholders from the health care industry to discuss how to counter the growing costs of pharmaceuticals (see story, p. 4). The Sept. 15 event, Solving for the Rising Cost of Complex Drugs, was sponsored by Express Scripts Holding Co. Following the conference, SPN spoke with Steve Miller, M.D., senior vice president and chief medical officer for Express Scripts, on some current… Read more
Check out all of the benefits, sample issues & more!